Rapid loss of vaccine-acquired hepatitis B surface antibody after three doses of hepatitis B vaccination in HIV-infected persons

Int J STD AIDS. 2014 Mar;25(3):201-6. doi: 10.1177/0956462413495820. Epub 2013 Aug 29.

Abstract

HIV-infected individuals have poor responses to hepatitis B vaccine and may have decreased durability of post-vaccination immunity. Retrospective chart review was conducted for HIV-1 positive individuals aged ≥18 years who received hepatitis B vaccine at an urban HIV clinic. A total of 309 patients completed three doses and 178 had post-vaccine serology testing after the third dose. In multivariate analysis, time between the third dose and the first post-vaccine serology testing at 180-359 days (OR = 0.077, p = 0.049) and at ≥360 days (OR = 0.065, p = 0.019) were associated with poor vaccine responses. A significant decrease in seropositivity appeared as early as 180 days after the third vaccine dose, suggesting a rapid loss of vaccine-acquired hepatitis B surface antibody in HIV-infected persons. Our findings suggest that hepatitis B surface antibody should be tested at 6 to 12 months after completing primary vaccine series in order to detect early secondary vaccine failure.

Keywords: AIDS; HIV; hepatitis B; human immunodeficiency virus; post-vaccination immunity; vaccination; vaccine response; viral disease.

MeSH terms

  • Antiviral Agents / therapeutic use
  • CD4 Lymphocyte Count
  • Dose-Response Relationship, Immunologic
  • Female
  • HIV Infections / complications
  • HIV Infections / immunology*
  • HIV-1 / immunology
  • Hepatitis B / complications
  • Hepatitis B / immunology
  • Hepatitis B / prevention & control*
  • Hepatitis B / virology
  • Hepatitis B Antibodies / blood*
  • Hepatitis B Antibodies / immunology
  • Hepatitis B Core Antigens / immunology*
  • Hepatitis B Vaccines / administration & dosage*
  • Hepatitis B Vaccines / therapeutic use
  • Hepatitis B virus / immunology
  • Humans
  • Immunization Schedule
  • Male
  • Retrospective Studies
  • Treatment Outcome
  • Vaccination / methods

Substances

  • Antiviral Agents
  • Hepatitis B Antibodies
  • Hepatitis B Core Antigens
  • Hepatitis B Vaccines